Author details

Full Name

Anton G Henssen

Affiliation

ORCID

Career Start Year

2013

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37503111	Coordinated inheritance of extrachromosomal DNA species in human cancer cells.	bioRxiv	2023
35687182	Pre-operative radiotherapy is associated with superior local relapse-free survival in advanced synovial sarcoma.	J Cancer Res Clin Oncol	2023
36134454	Rituximab therapy after pediatric hematopoietic stem cell transplantation can cause prolonged B-cell impairment and increases the risk for infections - a retrospective matched cohort study.	Haematologica	2023
37566080	Doxorubicin Changes the Spatial Organization of the Genome around Active Promoters.	Cells	2023
37868040	Mutational topography reflects clinical neuroblastoma heterogeneity.	Cell Genom	2023
37402719	Defining the landscape of circular RNAs in neuroblastoma unveils a global suppressive function of MYCN.	Nat Commun	2023
37142849	Parallel sequencing of extrachromosomal circular DNAs and transcriptomes in single cancer cells.	Nat Genet	2023
36753540	Single-cell profiling of alveolar rhabdomyosarcoma reveals RAS pathway inhibitors as cell-fate hijackers with therapeutic relevance.	Sci Adv	2023
37441939	Paediatric Strategy Forum for medicinal product development of DNA damage response pathway inhibitors in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.	Eur J Cancer	2023
35140176	Shedding Light on ecDNA Behavior Using CRISPR-Based Live-Cell Imaging.	Cancer Discovery	2022
35711922	Detection and Validation of Circular DNA Fragments Using Nanopore Sequencing.	Frontiers in Genetics	2022
36355400	Extrachromosomal DNA (ecDNA): an origin of tumor heterogeneity, genomic remodeling, and drug resistance.	Biochem Soc Trans	2022
35953594	Extrachromosomal DNA amplifications in cancer.	Nat Rev Genet	2022
35879366	Therapeutic targeting of ATR in alveolar rhabdomyosarcoma.	Nature Communications	2022
35689207	Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells.	Mol Cancer	2022
35613412	Genomic Evolution and Personalized Therapy of an Infantile Fibrosarcoma Harboring an <i>NTRK</i> Oncogenic Fusion.	JCO Precis Oncol	2022
36123406	The evolutionary dynamics of extrachromosomal DNA in human cancers.	Nat Genet	2022
35671543	Target actionability review to evaluate CDK4/6 as a therapeutic target in paediatric solid and brain tumours.	Eur J Cancer	2022
34980229	Correction to: Class I histone deacetylases (HDAC) critically contribute to Ewing sarcoma pathogenesis.	J Exp Clin Cancer Res	2022
35145302	The genomic and spatial mobility of extrachromosomal DNA and its implications for cancer therapy.	Nature Genetics	2022
34815394	Spatial and temporal intratumour heterogeneity has potential consequences for single biopsy-based neuroblastoma treatment decisions.	Nat Commun	2021
33801448	CD28 Co-Stimulus Achieves Superior CAR T Cell Effector Function against Solid Tumors Than 4-1BB Co-Stimulus.	Cancers	2021
34272609	The effect of adjuvant therapies on long-term outcome for primary resected synovial sarcoma in a series of mainly children and adolescents.	J Cancer Res Clin Oncol	2021
34267756	A Reproducible Bioprinted 3D Tumor Model Serves as a Preselection Tool for CAR T Cell Therapy Optimization.	Frontiers in Immunology	2021
33768209	Combined inhibition of Aurora-A and ATR kinase results in regression of -amplified neuroblastoma.	Nature Cancer	2021
34187933	Negative correlation of single-cell <i>PAX3:FOXO1</i> expression with tumorigenicity in rhabdomyosarcoma.	Life Sci Alliance	2021
34442335	Neuroblastoma Risk Assessment and Treatment Stratification with Hybrid Capture-Based Panel Sequencing.	J Pers Med	2021
34771652	Inhibiting Lysine Demethylase 1A Improves L1CAM-Specific CAR T Cell Therapy by Unleashing Antigen-Independent Killing via the FAS-FASL Axis.	Cancers	2021
34654445	Class I histone deacetylases (HDAC) critically contribute to Ewing sarcoma pathogenesis.	J Exp Clin Cancer Res	2021
34819668	ecDNA hubs drive cooperative intermolecular oncogene expression.	Nature	2021
31304977	Reflection of neuroblastoma intratumor heterogeneity in the new OHC-NB1 disease model.	Int J Cancer	2020
31844324	Extrachromosomal circular DNA drives oncogenic genome remodeling in neuroblastoma.	Nat Genet	2020
32415069	Oncogenic hijacking of a developmental transcription factor evokes vulnerability toward oxidative stress in Ewing sarcoma.	Nat Commun	2020
32296437	Tumor-Derived Extracellular Vesicles Impair CD171-Specific CD4 CAR T Cell Efficacy.	Frontiers in Immunology	2020
32107479	Publisher Correction: Extrachromosomal circular DNA drives oncogenic genome remodeling in neuroblastoma.	Nat Genet	2020
31932909	Synovial sarcoma disease characteristics and primary tumor sites differ between patient age groups: a report of the Cooperative Weichteilsarkom Studiengruppe (CWS).	J Cancer Res Clin Oncol	2020
32164354	High Specificity of BCL11B and GLG1 for EWSR1-FLI1 and EWSR1-ERG Positive Ewing Sarcoma.	Cancers (Basel)	2020
31869746	Small-Molecule Dual PLK1 and BRD4 Inhibitors are Active Against Preclinical Models of Pediatric Solid Tumors.	Translational Oncology	2020
32333465	Central memory phenotype drives success of checkpoint inhibition in combination with CAR T cells.	Molecular Carcinogenesis	2020
33199677	Enhancer hijacking determines extrachromosomal circular MYCN amplicon architecture in neuroblastoma.	Nat Commun	2020
32918070	Author Correction: PGBD5 promotes site-specific oncogenic mutations in human tumors.	Nat Genet	2020
32807987	Extrachromosomal DNA is associated with oncogene amplification and poor outcome across multiple cancers.	Nat Genet	2020
33230121	Publisher Correction: Oncogenic hijacking of a developmental transcription factor evokes vulnerability toward oxidative stress in Ewing sarcoma.	Nat Commun	2020
32504042	Partner independent fusion gene detection by multiplexed CRISPR-Cas9 enrichment and long read nanopore sequencing.	Nat Commun	2020
31391345	Prohibitin is a prognostic marker and therapeutic target to block chemotherapy resistance in Wilms' tumor.	JCI Insight	2019
31921698	Current and Future Treatment Strategies for Rhabdomyosarcoma.	Frontiers in Oncology	2019
30611741	Synergistic activity of BET inhibitor MK-8628 and PLK inhibitor Volasertib in preclinical models of medulloblastoma.	Cancer Letters	2019
31500597	CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing.	BMC Cancer	2019
30998507	Prohibitin promotes de-differentiation and is a potential therapeutic target in neuroblastoma.	JCI Insight	2019
30333322	Emerging functions of DNA transposases and oncogenic mutators in childhood cancer development.	JCI Insight	2018